Drug Safety

For many women, the journey to motherhood brings a sense of anticipation and joy. However, for those with rheumatoid arthritis (RA), this journey presents unique challenges. Women with RA often face…

The ORAL surveillance trial raised safety concerns that the janus kinase inhibitor (JAKi) tofacitinib was associated with an increased incidence of cancer and major adverse cardiovascular events…

Highlights from Day 3 at ACR24 included the plenary session presentation on Nipocalimab (previously reviewed), but the big highlight was the Lupus Nephritis guideline recommendations.2024 Updated ACR…

This has been an interesting ACR meeting in terms of PMR updates. I would argue that we are still far too wedded to glucocorticoids only in the management of PMR. Yes, some patients will do fine with…

The findings from ORAL Surveillance Study have been a dominant conversation at recent ACR Convergence, with the seminal findings and subsequent analyses a target of debate. This study comparing the…

The increased risk of cardiovascular disease in patients with rheumatoid arthritis has long been known (1). The association between increased levels of inflammation in rheumatoid arthritis and…

Here’s a collection of some of the best abstracts presented on day 2 of ACR 2024 as selected by the RheumNow faculty. If high +ANA and NO #rheumatic #disease LOOK 👀 at #LIVER#Autoimmune #…

Plenary sessions began the day, followed by thousands on the abstract floor. Here are a few of my favorite presentations from day 2 at ACR 2024.Statins and major adverse cardiovascular…

It’s been eight years, and here we are again. The ACR annual meeting was last in Washington DC in 2016, and there’s probably a lot about ACR 2024 in DC that seems familiar. Maybe for some, it’s the…

ACR Convergence 2024 opened today with a full slate of presentations, posters and specialty meetings.  The meeting began with a flip: the plenary sessions started at 9AM and the poster session…